The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration



Summary

The upcoming ECIL-10 guidelines for COVID-19 management in leukemia patients should thoroughly evaluate the potential benefits of convalescent plasma. While initial studies showed mixed results, further investigation is warranted considering the vulnerability of this patient population. Factors like antibody titer, timing of administration, and patient-specific characteristics should be carefully analyzed to identify potential responders. Incorporating convalescent plasma as a possible therapeutic option within the ECIL-10 guidelines could improve outcomes for leukemia patients severely affected by COVID-19, especially when other treatments prove ineffective. Further research specifically targeting this patient group is also crucial.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!